Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Parsa Abdi, a Memorial medical student, said that vitiligo is a challenging disease to live with. Vitiligo is a chronic ...

The Phase I ADC trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...

These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the years. While not all dividend stocks are the same, finding great companies ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...